Digital Pharma: Boehringer readies 'diabetes hub'

The healthcare professional section of Boehringer's Diabetes Health Lounge, the site will officially go live soon

Boehringer Ingelheim will shortly unveil a ‘digital diabetes hub’ that combines educational videos, research tools, educational games and information on type II diabetes.

Currently undergoing final checks, the new website is due to go live soon at diabeteshealthlounge.com and will be aimed at a European audience.

It is expected to have a wide range of features, include one that offers diabetes sufferers the opportunity to share their story.

The site’s video content will include a short educational animation on the mode of action of DPP-4 inhibitors, and a film that looks at diabetes through the eyes of those who live with the condition.

The Diabetes Health Lounge will be unveiled ahead of the anticipated launch date of Boehringer’s new type II drug diabetes linagliptin.

Boehringer’s new diabetes drug linagliptin

The oral once-daily tablet linagliptin is a member of the DPP-4 inhibitor class, which includes two already approved drugs - MSD's Januvia (sitagliptin) and Novartis' Galvus (vildagliptin).

Boehringer’s drug could also threaten older oral diabetes treatments such as GlaxoSmithKline's Avandia (rosiglitazone) as well as Onglyza (saxagliptin), a newer DPP-4 drug co-marketed by Bristol-Myers Squibb and AstraZeneca.

Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog He can be contacted via email, Twitter or LinkedIn.